Current Report Filing (8-k)
September 29 2020 - 6:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 29, 2020
Summit Therapeutics Inc.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware
|
|
001-36866
|
|
|
|
Pending
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
|
|
|
One Broadway, 14th Floor
Cambridge, MA
|
|
|
|
02142
|
|
|
|
(Address of Principal Executive Offices)
|
|
|
|
(Zip Code)
|
|
|
Registrant’s telephone number, including area code: 617-514-7149
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
|
|
|
|
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
|
Common stock, par value $0.01 per share
|
SMMT
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 8.01 Other Events
Summit Therapeutics Inc., a Delaware corporation (the “Company”) is filing this Current Report on Form 8-K to provide certain disclosures for the eleven month period ended December 31, 2019 (set forth in Exhibit 99.1 hereto and incorporated herein by reference) and the quarterly period ended June 30, 2020 (set forth in Exhibit 99.2 hereto and incorporated by reference). Except as otherwise noted, the disclosures relate to the Company’s predecessor, Summit Therapeutics plc, a public limited company incorporated under the laws of England and Wales with the Registrar of Companies of England and Wales, United Kingdom.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit Number
|
|
Description
|
|
|
|
|
|
99.1
|
|
|
|
99.2
|
|
|
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUMMIT THERAPEUTICS INC.
|
|
|
|
|
|
|
|
|
|
|
|
Date: September 29, 2020
|
|
|
|
By:
|
|
/s/ Robert W. Duggan
|
|
|
|
|
|
|
|
Robert W. Duggan
Chief Executive Officer
|
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024
